Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Objective This multicenter, double-blind, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents. RESEARCH DESIGN AND METHODS: The primary end point was HbA 1c change from baseline after 26 weeks' treatment. After an 8-week run-in to optimize basal insulin, subjects were randomized (1:1) to mealtime faster aspart ( n = 345) or IAsp ( n = 344), titrated using a simple daily patient-driven algorithm, plus insulin glargine U100 and metformin. Results HbA 1c change was -1.38% (faster aspart) and -1.36% (IAsp); mean HbA 1c was 6.6% for both groups. Faster aspart demonstrated noninferiority versus IAsp in reducing HbA 1c (estimated treatment difference [ETD] [95% CI] -0.02% [-0.15; 0.10]). Both treatments improved postprandial plasma glucose (PPG) control; the PPG increment (liquid meal test) was statistically significant in favor of faster aspart after 1 h (ETD [95% CI] -0.59 mmol/L [-1.09; -0.09]; -10.63 mg/dL [-19.56; -1.69]; P = 0.0198), but not after 2-4 h. Change from baseline in fasting plasma glucose, body weight, and overall severe/blood glucose-confirmed hypoglycemia rates (rate ratio [RR] [95% CI] 1.09 [0.88; 1.36]) were similar between treatments. Postmeal hypoglycemia (0-2 h) rates were 2.27 (faster aspart) and 1.49 (IAsp) per patient-year of exposure (RR [95% CI] 1.60 [1.13; 2.27]). Conclusions Faster…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhaled insulin with a faster peak of action and shorter duration is also available as prandial insulin, with the requirement of using repeated inhaled correctional insulin doses after 1 to 2 hours postmeal.1158,1159”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1159]
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Andrea, D., Kakuk, P., & Judit, S. (2014) · University of Debrecen Electronic Archive (University of Debrecen) · Cited by 1,954
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia was defined according to the ADA classification (17).”
BackgroundMethodBeta Cell Dysfunction and Insulin Resistance
Cerf, M. E. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00037 · Cited by 964 · cited 1×
“Given the heterogeneity of type 2 diabetes, both in regard to insulin resistance and residualb-cell function (24), that similar overall glycemic control was achieved with both faster aspart and IAsp is unsurprising.”
BackgroundDungan, K. M., Buse, J. B., Largay, J., Kelly, M. M., Button, E. A., Kato, S., & Wittlin, S. (2006) · Diabetes Care · doi:10.2337/dc06-1910 · Cited by 242
Home, P. D., Lindholm, A., Riis, A., & for the European Insulin Aspart Study Group (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00380.x · Cited by 232
Heise, T., Pieber, T. R., Danne, T., Erichsen, L., & Haahr, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0514-8 · Cited by 182 · cited 2×
“9 min), twofold higher insulin concentration, and 74% greater insulin action in the first 30min versus IAsp (10).”
BackgroundResultRussell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177
Self-citationDavidson, P. C., Hebblewhite, H. R., Steed, R. D., & Bode, B. W. (2008) · Endocrine Practice · doi:10.4158/ep.14.9.1095 · Cited by 167 · cited 1×
“Recommending a regimen in which the basal dose comprises ,50% of the overall insulin dose is preferable for achieving optimal glycemic control in basal-bolus treatment (27).”
BackgroundSelf-citationWhen basal insulin therapy in type 2 diabetes mellitus is not enough—what next?
Raccah, D., Bretzel, R. G., Owens, D., & Riddle, M. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.733 · Cited by 112 · cited 2×
“Black or African American 22 (6) 18 (5) 40 (6)”
BackgroundHome, P. D. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12501 · Cited by 90 · cited 1×
“However, there remains an unmet need for insulin analogs with an even faster onset of action than rapid-acting insulin analogs, which could potentially achieve better PPG control (7,8).”
BackgroundGiugliano, D., Chiodini, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2015) · Endocrine · doi:10.1007/s12020-015-0718-3 · Cited by 89 · cited 2×
“Many people with diabetes fear hypoglycemia; however, although a high proportion of subjects achievedHbA1c,7%, hypoglycemia rates were comparable with those previously reported (21), and no statistically significant differences were observed between the two treatments.”
ResultUltrafast-Acting Insulins: State of the Art
Heinemann, L., & Muchmore, D. B. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600402 · Cited by 89 · cited 1×
“However, there remains an unmet need for insulin analogs with an even faster onset of action than rapid-acting insulin analogs, which could potentially achieve better PPG control (7,8).”
BackgroundMeneghini, L., Mersebach, H., Kumar, S., Svendsen, A. L., & Hermansen, K. (2011) · Endocrine Practice · doi:10.4158/ep10367.or · Cited by 79 · cited 1×
“However, a treatto-target trial of well-controlled subjects with type 2 diabetes showed that ;75% of subjects initiated with one bolus injection eventually required a full basal-bolus regimen (30), so it is of value to assess faster aspart in the same regimen.”
BackgroundThe glucose triad and its role in comprehensive glycaemic control: current status, future management
Ceriello, A. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02517.x · Cited by 78 · cited 1×
“As b-cell function decreases further, maintaining target HbA1c levels becomes challenging, even when target fasting plasma glucose (FPG) levels have been achieved (2), and further therapeutic intensification may be required (3).”
Backgroundvan Dieren, S., Czernichow, S., Chalmers, J., Kengne, A. P., de Galan, B. E., Poulter, N., Woodward, M., Beulens, J. W. J., Grobbee, D. E., van der Schouw, Y. T., et al. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01556.x · Cited by 50 · cited 1×
“7 kg over 26 weeks for both treatment groups, which is typical of the weight gain associated with intensive insulin regimens (28).”
BackgroundRodbard, H. W., Tripathy, D., Vidrio-Velázquez, M., Demissie, M., Tamer, S. C., & Piletič, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12955 · Cited by 49
Peter, R., Dunseath, G. J., Luzio, S. D., Chudleigh, R. A., Choudhury, S. R., & Owens, D. R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02809.x · Cited by 36
“Mild dysglycemia” in type 2 diabetes: to be neglected or not?
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.004 · Cited by 31 · cited 1×
“Several studies have documented that in type 2 diabetes, the relative contribution of PPG to excess hyperglycemia increases as HbA1c levels approach target (4,5).”
BackgroundHeller, S., Bode, B., Kozlovski, P., & Svendsen, A. L. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12060 · Cited by 28 · cited 1×
“47 mmol/L (90-min PPG value); analysis of average change in PPG increment gave similar results (25).”
ResultSelf-citationKing, A. B. (2010) · Endocrine Practice · doi:10.4158/ep09308.or · Cited by 28
Wang, Y.-Q., Zhang, Y. L., Wang, Y., Lei, C., & Sun, Z. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2278 · Cited by 21 · cited 1×
“Mealtime faster aspart and IAsp were effective in controlling PPG (assessed by both the meal test and SMPG) and improved levels of 1,5-AG, a marker for postprandial hyperglycemia (22,23).”
Method
Research works printed but not linked: 1
- Buckley, 2016, Mechanistic analysis into the mode of action of niacinamide in faster-acting insulin aspart, Diabetes Technol Ther, 18, A291
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177
Self-citationPharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Rosenstock, J., Frías, J. P., Rodbard, H. W., Tofé, S., Sears, E., Huh, R., Fernández Landó, L., & Patel, H. (2023) · JAMA · doi:10.1001/jama.2023.20294 · Cited by 156
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Lipscombe, L., Butalia, S., Dasgupta, K., Eurich, D. T., MacCallum, L., Shah, B. R., Simpson, S., & Senior, P. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.001 · Cited by 153
Metadata
- Authors
- Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W.
- Affiliations
- University of Alberta (CA)
- Jefferson City Medical Group, Jefferson City, MO
- Bangor University (GB)
- Diabetes Clinical Trials, Chattanooga, TN
- Diabetes, Endocrinology and General Medicine, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, U.K.
- Protenium Clinical Research, Hurst, TX
- Novo Nordisk (Denmark) (DK)
- Atlanta Diabetes Associates (US)
- Corresponding author
- Bowering, Keith
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-05-08
- Volume
- 40
- Issue
- 7
- Pages
- 951-957
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2612230287
- Cited by
- 119
- References
- 29
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 9 · 2023: 8 · 2022: 17 · 2021: 14 · 2020: 17 · 2019: 17 · 2018: 22 · 2017: 9
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin aspart, fast-acting insulin, multiple daily insulin injections, type 2 diabetes, inadequate glycemic control, HbA1c, postprandial blood glucose, hypoglycemia, insulin glargine, metformin, non-inferiority, insulin dose adjustment, oral antidiabetic drugs, body weight
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Postprandial Period, Endpoint Determination, Insulin Aspart, Meals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.